Computer Science · Artificial Intelligence
Comment on Brenner et al, page 2521, and Kumar et al, page 2516 The road to cure in multiple myeloma
Irene M. Ghobrial, Kenneth C. Anderson, Jerome Lipper, Multiple Myeloma Center
See on the mapAbstract
For the past several decades, multiple myeloma (MM), the second most common hematologic malignancy, has been considered a fatal disease with a median survival of 5 years. However, recent advances in the understanding of the molecular patho-genesis of MM have led to new treatment strategies. Thalidomide, bortezomib, and lenalido-mide, which target the tumor cell in its bone marrow microenvironment and over-come cell adhesion–mediated drug resistance to conventional therapies,1 were first shown to be active alone and in combination with dexa-methasone in patients with relapsed refractory MM. Subsequently, each has been combined with dexamethasone for transplantation candi-dates and with melphalan and prednisone for nontransplantation candidates with newly diagnosed disease.2,3 Remarkably, thalidomide